One-Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study

被引：8

作者：

Dalal, Rahul S. ^{[1
]}

Kallumkal, Govind ^{[2
]}

Cabral, Heidy J. ^{[1
]}

Barnes, Edward L. ^{[3
]}

Allegretti, Jessica R. ^{[1
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA

[2] Univ N Carolina, Dept Med, Chapel Hill, NC USA

[3] Univ N Carolina, Dept Med, Div Gastroenterol, Chapel Hill, NC USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 08期

关键词：

small molecule; Janus kinase inhibitor; inflammatory bowel disease; remission; biologic; MAINTENANCE THERAPY; INDUCTION;

D O I：

10.14309/ajg.0000000000002746

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

INTRODUCTION: The comparative effectiveness of upadacitinib and tofacitinib for ulcerative colitis (UC) is poorly understood. METHODS: In this retrospective cohort study, we compared steroid-free clinical remission (SFCR) and endoscopic response/remission at 52 weeks among adults initiating upadacitinib or tofacitinib for UC. RESULTS: A total of 155 patients initiated upadacitinib (n = 81; 30% prior tofacitinib exposure) or tofacitinib (n = 74; 0% prior upadacitinib exposure). After inverse probability of treatment-weighted logistic regression, upadacitinib was associated with significantly higher odds of SFCR (odds ratio 3.01, 95% confidence interval 1.39-6.55) vs tofacitinib. There were no differences for endoscopic response/remission. DISCUSSION: Upadacitinib was more effective at achieving SFCR in UC at 52 weeks vs tofacitinib.

引用

页码：1628 / 1631

页数：4

共 50 条

[41] Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
Parra, Rogerio S.
Froes, Renata de Sa Brito
Magro, Daniela Oliveira
Ferreira, Sandro da Costa
de Mello, Munique Kurtz
de Azevedo, Matheus Freitas Cardoso
Damiao, Aderson Omar Mourao Cintra
Carlos, Alexandre de Sousa
Barros, Luisa Leite
de Miranda, Maria Luiza Queiroz
Vieira, Andrea
Moraes Sales, Marcos Paulo
Gabot, Gilmara
Cassol, Ornella Sari
Alves Junior, Antonio Jose Tiburcio
Lubini, Marcio
Machado, Marta Brenner
Flores, Cristina
Teixeira, Fabio Vieira
Coy, Claudio Saddy Rodrigues
Sassaki, Ligia Yukie
Feres, Omar
Chebli, Julio Maria Fonseca
Zaltman, Cyrla
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (12S): : S25 - S25
[42] Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons
Reinisch, Walter
Melmed, Gil Y.
Nakase, Hiroshi
Seidelin, Jakob
Ma, Christopher
Xuan, Si
Tran, Jacinda
Remple, Valencia
Wegrzyn, Lani
Levy, Gweneth
Sanchez Gonzalez, Yuri
Panaccione, Remo
ADVANCES IN THERAPY, 2024, 41 (10) : 3832 - 3849
[43] REAL-WORLD CLINICAL OUTCOMES OF UPADACITINIB FOR ULCERATIVE COLITIS AT 8-12 WEEKS: A MULTICENTER RETROSPECTIVE COHORT STUDY
Dalal, Rahul S.
Sninsky, Jared A.
Radcliffe, Marlana
Bachour, Salam
Barnes, Edward L.
McClure, Emma L.
Allegretti, Jessica R.
GASTROENTEROLOGY, 2023, 164 (06) : S1125 - S1125
[44] Real-World Clinical, Endoscopic, and Safety Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study
Dalal, Rahul
Kallumkal, Govind
Cabral, Heidy
Bachour, Salam
Barnes, Edward
Allegretti, Jessica R.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S850 - S851
[45] Effect of Tofacitinib on Hemostasis in Patients with Ulcerative Colitis: a Comparative Ex Vivo Study
Baldan-Martin, M.
Sanchez Sanchez, C.
Suarez Trujillo, F.
Ramirez, C.
Soleto, I
Mercado, J.
Orejudo, M.
Martinez, P. J.
Rubio Collado, C.
Orts, M.
Rubio Franco, M. J.
Planas, A.
Acedo, N.
Butta, N.
Chaparro, M.
Gisbert, J. P.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i483 - i485
[46] EFFECTIVENESS OF UPADACITINIB FOR PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS: A CASE-CONTROL STUDY
Berinstein, Jeffrey
Karl, Taylor A.
Patel, Anish
Dolinger, Michael T.
Barrett, Terrence
Ahmed, Waseem
Click, Benjamin
Steiner, Calen A.
Dulaney, David
Levine, Jake
Hassan, Syed Adeel
Perry, Courtney
Flomenhoft, Deborah
Ungaro, Ryan C.
Aintabi, Daniel
Berinstein, Elliot
Sheehan, Jessica L.
Cohen-Mekelburg, Shirley
Stidham, Ryan
Bishu, Shrinivas
Colombel, Jean Frederic
Regal, Randolph
Higgins, Peter D.
GASTROENTEROLOGY, 2024, 166 (05) : S1425 - S1425
[47] Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study
Dragoni, Gabriele
Innocenti, Tommaso
Amiot, Aurelien
Castiglione, Fabiana
Melotti, Laura
Festa, Stefano
Savarino, Edoardo Vincenzo
Truyens, Marie
Argyriou, Konstantinos
Noviello, Daniele
Molnar, Tamas
Bouillon, Vincent
Bezzio, Cristina
Eder, Piotr
Fernandes, Samuel
Kagramanova, Anna
Armuzzi, Alessandro
Oliveira, Raquel
Viola, Anna
Ribaldone, Davide Giuseppe
Drygiannakis, Ioannis
Vigano, Chiara
Calella, Francesca
Gravina, Antonietta Gerarda
Pugliese, Daniela
Chaparro, Maria
Ellul, Pierre
Vieujean, Sophie
Milla, Monica
Caprioli, Flavio
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (08): : 1525 - 1535
[48] One-year success rates of targeted therapy in Ulcerative Colitis patients revisited
Creemers, R.
van Andel, E.
Wintjens, D.
van Bodegraven, A.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1149 - I1150
[49] ULCERATIVE COLITIS IN FINLAND .2. ONE-YEAR INCIDENCE IN ALL HOSPITALS
LINDEN, G
MOLLER, C
DISEASES OF THE COLON & RECTUM, 1971, 14 (04) : 264 - +
[50] One-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib Versus Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States
Dalal, R.
Sharma, P.
Bains, K.
Pruce, J.
Allegretti, J.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 677 - 678

← 1 2 3 4 5 →